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Background: We used evidence-based laboratory med-
icine principles to compare the diagnostic accuracy of
brain natriuretic peptide (BNP) and the N-terminal part
of the propeptide of BNP (NT-proBNP) assays for the
diagnosis of heart failure.
Methods: In May 2006, we performed a computerized
literature search of the online National Library of Med-
icine to select studies specifically designed to compare
the diagnostic accuracy of BNP and NT-proBNP assays.
The comparison took into account the area under the
curve and diagnostic odds ratio (DOR) derived from
ROC analysis of original studies.
Results: Both BNP and NT-proBNP assays were found
to be clinically useful for the diagnosis of heart failure.
Metaanalysis of these data was difficult because of the
heterogeneity of data regarding patient population, di-
agnostic criteria, end-points, and immunoassay methods
for both BNP and NT-proBNP. Separate metaanalyses
were performed for acute and chronic heart failure. In
chronic heart failure, the diagnostic DOR for BNP (8.44,
95% CI 4.66–15.30) was not significantly different from
that of NT-proBNP (23.36, 95% CI 9.38–58.19). In pa-
tients with acute heart failure, the mean DOR for BNP
(16.46, 95% CI 10.65–25.43) was not significantly differ-
ent from that of NT-proBNP (18.61, 95% CI 12.99–26.65).
Conclusion: Our results indicate that both BNP and
NT-proBNP assays have a high degree of diagnostic
accuracy and clinical relevance for both acute and
chronic heart failure.
© 2007 American Association for Clinical Chemistry
The cardiac natriuretic hormones (CNHs)3 are a family of
related peptide hormones produced and secreted by
cardiomyocytes. CNHs have potent diuretic, natriuretic,
and vascular smooth muscle–relaxing effects and also
carry out complex interactions with the neurohormonal
system (1 ). Although the role of CNHs in the identifica-
tion and management of individuals with asymptomatic
ventricular dysfunction remains to be fully clarified (2 ),
the clinical usefulness of CNH assays, especially B-type
natriuretic peptide (BNP) and the N-terminal part of the
propeptide of BNP (NT-proBNP), has been confirmed for
screening of heart disease, stratification of patients with
congestive heart failure, detection of left ventricular sys-
tolic and/or diastolic dysfunction, and differential diag-
nosis of dyspnea (3, 4 ). Furthermore, the Task Force of the
European Society of Cardiology for the diagnosis and
treatment of both acute (5 ) and chronic (6 ) heart failure
recently confirmed that assays of CNHs (especially of
BNP-related peptides) should be included in the first
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steps of the diagnostic algorithm, along with clinical
examination, electrocardiogram, and chest x-ray
examination.
The use of BNP or NT-proBNP measurement in clinical
practice requires the commercial availability of robust and
fully automated immunoassay methods (3, 7, 8 ). Al-
though several studies have been published recently on
the biochemical characteristics and pathophysiological
relevance of BNP and NT-proBNP, no systematic reviews
have been reported that specifically aimed to compare the
diagnostic accuracy of commercial immunoassays for
different B-type related natriuretic peptides.
Several recent studies suggested that the diagnostic
accuracy of CNH immunoassay methods depends not
only on the peptide measured but also on the platform
used (3, 7, 8 ). Commercial immunoassays for BNP use
different standard materials and antibodies that are spe-
cific for different epitopes located on the N-terminus,
C-terminus, or cysteine-ring of the peptide chain (8 ).
Experimental data support the hypothesis that BNP is
cleaved by several plasma proteases; therefore, these
enzymatic cleavages, particularly the one at the N-termi-
nus, must be considered when choosing epitopes for
antibody production and immunoassay design (3, 7, 8 ).
Because of their different biochemical and physiological
characteristics, BNP and NT-proBNP measurements may
have different advantages (1, 3 ). BNP is a shorter peptide
hormone than NT-proBNP (32 vs 76 amino acids), is
inactive, and has a shorter plasma half-life (15–20 min vs
1 h) (1 ). For these reasons, BNP might show a better
correlation with rapid changes in activation of neurohor-
mone systems and hemodynamics than NT-proBNP. On
the other hand, NT-proBNP degrades more slowly both in
vivo and in vitro, has a higher circulating concentration,
and is more stable, with less biological variability, than
BNP (1 ).
We performed a computerized online literature search
on the National Library of Medicine using as keywords
“BNP assay” and “NT-proBNP assay”. We report results
of our metaanalysis of selected studies specifically de-
signed to compare the diagnostic accuracy of BNP and
NT-proBNP assays for the differential diagnosis of heart
failure.
Materials and Methods
metaanalysis
In May 2006, we performed a computerized literature
search on the National Library of Medicine (i.e., PubMed
access to MEDLINE citations, http://www.ncbi.nlm.
nih.gov/PubMed/) using the keywords “BNP assay”
(1600 articles) and “NT-proBNP assay” (450 articles).
Then, we refined the metaanalysis to include only the
studies specifically designed to compare the accuracy of
BNP and NT-proBNP assays for the diagnosis of heart
failure. To evaluate the diagnostic accuracy of these
assays we followed the process usually recommended for
systematic review of diagnostic accuracy of medical tests
(9–13). This systematic review contained only data gen-
erated by parallel analysis of a BNP and an NT-proBNP
assay on the same set of specimens. The criteria for
excluding a study from the metaanalysis were (a) incom-
plete data on immunoassay methods used, (b) absence of
ROC analysis, and (c) absence of diagnostic end-point. In
addition, in cases in which several published studies
(usually large clinical trials) included the same population
(control or patient group), we selected only 1 article, the
most recent or complete. One study compared the diag-
nostic accuracy of 5 commercial methods for BNP with
that of the electrochemiluminescence immunoassay
(ECLIA) method for NT-proBNP (7 ). Because the diag-
nostic accuracy did not significantly differ among the
BNPmethods, only data concerning the IRMAmethod for
BNP (which performed best in the study) were included
in the metaanalysis. This study also demonstrated that
differences in diagnostic accuracy are more evident when
patients with mild heart failure [New York Heart Associ-
ation (NYHA) classes I and II] are considered rather than
patients with severe disease (NYHA classes III and IV).
For this reason, when studies (14–19) offered different
options for the end-point (severity of left ventricular
dysfunction, structural myocardial disease and symp-
toms) we chose the values associated with diagnosis of
milder disease.
The statistical comparison was made by taking into
account the area under the curve (AUC) of an ROC
analysis and the values of the diagnostic odds ratio
(DOR). This double approach was chosen because some
articles did not report some statistical parameters, such as
confidence limits for AUC or sensitivity/specificity at
cutoff values. Thus we could not use only 1 type of
accuracy test (e.g., consider only the AUC or DOR values)
to analyze data from all studies.
We performed statistical analyses with a Macintosh
PowerBook G4 using R statistical software (Version R
2.4.1, December 2006, by the R Foundation for Statistical
Computing; section, Meta Package for metaanalysis),
which is a free software environment for statistical com-
puting and graphics (http://www.r-project.org). In par-
ticular, the random-effects model according to the DerSi-
monian–Laird method for pooled AUC and DOR values
and the Q test for heterogeneity statistics were used. For
all studies the counts used for the calculation of 2  2
tables were deduced from reported sensitivity, specificity,
disease prevalence, and total number of patients studied.
Some data concerning the study by Clerico et al. (7 ) were
obtained directly from the authors. To test the heteroge-
neity of data, the true-positive rates were plotted against
the false-positive rates on a Moses-type summary ROC
curve (sROC) (13 ) (Fig. 1). In this plot, the area of the
circles is proportional to the inverse of the SE, as reported
in the original studies. To calculate the pooled AUC and
DOR values, both fixed-effects and random-effects mod-
els were used: however, we chose to report only data
obtained with the random-effects model with inverse
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variance weighting (Figs. 2, 3, and 4), owing to the
significant heterogeneity of data (11 ), as also previously
reported in the literature (4 ).
Results
To reduce the heterogeneity among the clinical studies (as
demonstrated by data reported in Fig. 1), we divided the
metaanalysis into 2 parts according to the different clini-
cal settings of patients with acute and chronic heart
failure.
chronic heart failure
We included 15 clinical studies specifically designed to
compare the diagnostic accuracy of BNP and NT-proBNP
assays in patients with left ventricular dysfunction
and/or structural myocardial disease and symptoms. The
characteristics and number of patients enrolled, the type
of immunoassay, and the diagnostic end-points of these
studies are reported in Table 1. Echocardiographic evalu-
ation was the reference method for the assessment of
myocardial dysfunction (both systolic and systodiastolic)
in all studies; in only 1 study (20 ), diagnosis was per-
formed by use of echocardiographic evaluation combined
with clinical criteria (including clinical history, physical
examination, electrocardiogram, and chest x-ray).
In the 15 studies reported in Table 1, different immu-
noassay methods were used to measure BNP and NT-
proBNP. The most frequently used immunoassay for
NT-proBNP (11 studies) was the ECLIA method (Elecsys
System, Roche Diagnostics). Other immunoassays used
were an EIA (Biomedica; 3 studies) and an in-house RIA
(1 study).
Commercial BNP methods used (Table 1) were an
IRMA (Shionoria; 7 studies), a point-of-care-testing
method (TRIAGE System, Biosite; 5 studies), the ADVIA
method (Centaur System, Bayer HealthCare; 3 studies),
the MEIA method (AxSYM System, Abbott Laboratories;
2 studies), and an in-house RIA (1 study). The values for
AUC and sensitivity/specificity reported for BNP and
NT-proBNP assays in the original articles are also in-
cluded in Table 1.
Higher AUC values were observed with the ECLIA
NT-proBNP method than with the 5 commercial BNP
assays, whereas other NT-proBNP methods did not show
AUC values different from BNP methods (Table 1). Meta-
analysis revealed no significant difference between diag-
nostic accuracy of NT-proBNP and BNP assays for 12
studies reporting the AUC and its respective 95% confi-
dence interval (CI) values (mean AUC for NT-proBNP
0.8308, 95% CI 0.7738–0.8878, test of heterogeneity P
0.0001; mean AUC for BNP 0.8182, 95% CI 0.7561–
0.8803, test of heterogeneity P 0.0001) (7, 14–24 ).
For Moses-type sROC curve plots of true-positive vs
false-positive rates for individual studies including pa-
tients with chronic heart failure (Fig. 1A), the Q test of
heterogeneity demonstrated a wide dyshomogeneity
among all studies (P 0.0001), including both BNP and
NT-proBNP results. To analyze results of the 12 studies
reporting the sensitivity and specificity at cutoff values,
we used the sROC approach, which converts each pair of
sensitivity and specificity data into a single measure of
accuracy (DOR) (9–13), calculated with a random effects
model, for BNP (Fig. 2A) and NT-proBNP (Fig. 2B). The
pooled DOR for the BNP assay (DOR 8.44, 95% CI
Fig. 1. Moses-type sROC curve for true-positive vs false-positive rates evaluated in patients with (A) chronic heart failure or (B) acute heart failure.
Open circles and dotted line indicate BNP results, and black filled circles and line indicate NT-proBNP results.
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4.66–15.30, test of heterogeneity P 0.0001; Fig. 2A) was
not significantly different from that for the NT-proBNP
assay (23.36, 95% CI 9.38–58.19, test of heterogeneity P
0.0001; Fig. 2B).
acute heart failure
Our 2nd metaanalysis included 9 clinical studies (25–33)
specifically designed to compare the diagnostic accuracy
of BNP and NT-proBNP assays in patients with symp-
toms of acute heart failure treated in an emergency
department. The characteristics and numbers of patients
enrolled, the type of immunoassay, and the diagnostic
end-points of these studies are reported in Table 2, and
the metaanalysis results are reported in Figs. 3 and 4. All
studies except the study by Chien et al. (31 ) used clinical
and echocardiographic criteria for the diagnosis of acute
heart failure. Chenevier-Gobeaux et al. (27 ) studied pa-
tients with acute heart failure associated with moderate to
severe renal dysfunction, stratified in some groups ac-
cording to the glomerular filtration rate. Therefore we
Fig. 2. Forest plots of DOR values for (A) BNP and (B) NT-proBNP assays reported for studies of patients with chronic heart failure (Table 1).
The black diamond with the dotted line indicates the pooled DOR with 95% CI.
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separately analyzed patient data divided into 3 groups on
the basis of glomerular filtration rates: 30, 30–59, and
60–90 mL  min1  (1.73 m2)1.
All studies but 1 (32 ) used ECLIA methods for NT-
proBNP measurement and 7 studies used the TRIAGE
method or the MEIA method for BNP measurement
(Table 2). The results of metaanalyses including the 6
studies reporting AUC values are shown in Fig. 3A for
BNP and Fig. 3B for NT-proBNP. We observed no signif-
icant difference in diagnostic accuracy between NT-
proBNP and BNP. The mean AUC values calculated with
a random-effects model were 0.8391 for BNP (95% CI
0.7816–0.8966, test of heterogeneity P0.0001) and 0.8689
for NT-proBNP (95% CI 0.8287–0.9091, test of heteroge-
neity P 0.0009). With metaanalyses based on calculation
of the DOR values for BNP and NT-proBNP (Fig. 4), the
pooled DOR estimate calculated by random effects model
for BNP was 16.46 (95% CI 10.65–25.43, test of heteroge-
neity P  0.0462) and for NT-proBNP was 18.61 (95% CI
12.99–26,65, test of heterogeneity P  0.2654), with no
significant difference betweeen BNP and NT-proBNP
(Fig. 4).
Fig. 3. Forest plots of AUC values for BNP (A) and NT-proBNP (B) assays reported for studies of patients with acute heart failure (Table 2).
The black diamond with the dotted line indicates the pooled DOR with 95% CI.
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Discussion
Several different methods can be used to measure diag-
nostic accuracy, but most diagnostic accuracy studies
present estimates of sensitivity and specificity, either
alone or in combination with other measures (9–13).
Pooling pairs of sensitivity and specificity to perform a
metaanalysis is not a straightforward process, however,
because these measures are often negatively correlated
within studies. Some authors have suggested that the
sROC approach should be the method of choice for
metaanalysis of studies reporting paired sensitivity and
specificity data (9–13). The sROC approach converts each
sensitivity and specificity data pair into a single measure
of accuracy, the DOR (9–13). This approach has been used
for systematic review of the diagnostic accuracy of mea-
surement of atrial natriuretic peptide (ANP)- and BNP-
related peptides for heart failure (4 ). In the present study,
we used the sROC approach (12 ) to compare the diagnos-
tic accuracy of BNP and NT-proBNP assays in patients
with acute or chronic heart failure. In particular, because
Fig. 4. Forest plots of DOR values for BNP (A) and NT-proBNP (B) assays reported for studies of patients with acute heart failure (Table 2).
The black diamond with the dotted line indicates the pooled DOR with 95% CI.
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the AUC with respective 95% CI or sensitivity/specificity
values were not reported in all studies included in Tables
1 and 2, we made calculations with both pooled AUC and
DOR values by means of a random effects model with
inverse variance weighting.
Our results confirm that the measurement of both BNP
and NT-proBNP shows a high degree of diagnostic accu-
racy and clinical relevance for the diagnosis of heart
failure (3, 4). Furthermore, the present study demon-
strates a wide dyshomogeneity among the results of
published studies that used both BNP and NT-proBNP
immunoassays. The great dyshomogeneity and the low
number of studies suggest the need for caution when
interpretating clinical results reported in the literature.
The results reported in Fig. 1 suggest that the dysho-
mogeneity is greater for the studies concerning patients
with chronic heart failure (Fig. 1A) than for those with
acute heart failure (Fig. 1B). This finding is in part
expected, because patients referred to the emergency
department are relatively more clinically homogeneous
than those enrolled in studies on chronic stable heart
failure. The management of patients suspected to have
acute heart failure is mainly based on the differential
diagnosis of dyspnea in the emergency department and
intensive coronary care unit. According to the definition
of acute heart failure (5 ), patients with severe symptom-
atic disease (NYHA class III-IV) may present either with
de novo dyspnea without previously ascertained cardiac
disease or with an acute decompensation of chronic heart
failure. On the other hand, patients with heart failure
defined as chronic tend to have milder, more stable
disease (6 ). Moreover, studies of the diagnostic accuracy
of BNP and NT-proBNP assay for diagnosis of heart
failure usually enroll some patients who have mild symp-
toms (NYHA class II) or even are asymptomatic and have
only structural disease (NYHA class I). Patients with
chronic heart failure are usually enrolled and studied in
cardiological outpatient clinics or during community
screening of large general population studies performed
with the collaboration of general practitioners. Dyshomo-
geneity also occurs as the result of differing inclusion (or
exclusion) criteria for patient enrollment; in particular, for
some studies exclusion criteria included the presence of
some degree of renal failure (14, 18, 23, 24, 34, 35 ). Thus,
the prevalence and severity of heart failure varied greatly
among the studies, a circumstance that clearly affected the
diagnostic accuracy of the BNP and NT-proBNP assays
(3, 4 ). Finally, although all studies reported that the
diagnosis of acute or chronic heart failure was made
according to the most recent international guidelines
(5, 6, 36 ), the authors actually chose different diagnostic
end-points (Tables 1 and 2). Another cause of dyshomo-
geneity was the use of different methods for BNP and
NT-proBNP measurement (Tables 1 and 2). This effect is
even more impressive for the NT-proBNP assays. The
analytical performance and clinical results of ECLIA
methods differ greatly compared with other commercial
or in-house methods for NT-proBNP measurement (Ta-
bles 1 and 2). For these reasons, our data confirm that the
cutoff values are method dependent (3, 7, 8, 37 ).
In conclusion, our results, taken as a whole, indicate that
both BNP and NT-proBNP assays, without significant
differences between the 2 analytes, have high diagnostic
accuracy and clinical relevance for assessment of both
acute and chronic heart failure patients.
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